News
Entering 100 Cities, Engaging 1,000 Enterprises, Connecting 10,000 Households | The Wengling Pharmaceutical Enterprises Symposium Successfully Held at Wanbangde China-Africa Science Park
Date:
29 Apr,2022
To further implement the "Thirty Opinions of the Taizhou Municipal Administration for Market Regulation on Further Optimizing the Business Environment and Strengthening Market Entities," the event aimed to continuously boost the vitality of pharmaceutical market players and help rekindle new achievements in the private economy. On April 22, 2022, the "Enter 100 Cities, Reach 1,000 Enterprises, Connect with 100 Households" service initiative—the Wenling City Pharmaceutical Enterprise Symposium—was held at Wanbangde China-Africa Science Park. Attendees included Ye Xingfu, Member of the Party Committee and Deputy Director of the Taizhou Municipal Administration for Market Regulation, along with heads from relevant departments; Zhu Keqiang, Member of the Party Committee and Deputy Director of the Wenling Municipal Administration for Market Regulation, also attended alongside departmental leaders. Representatives from 12 leading pharmaceutical companies in Wenling—including Wanbangde Group, Wanbangde Pharmaceutical Group, Wanbangde Medical Technology, Kangkang Medical Devices, the First City Hospital, the City Central Hospital, and Rui Rentang—participated in the meeting.
Before the meeting, Director Ye and his delegation visited the Wanbangde China-Africa Science and Technology Park’s product showroom, polymer workshop, sterilization facility, and fully automated, intelligent, three-dimensional warehouse, gaining a brief overview of the park’s development focus and industrial plans.
The Wanbangde China-Africa Science and Technology Park (Medical Device Industry), construction of which began in 2019, is a key provincial-level project in Zhejiang Province. It serves as the Group’s response to the Belt and Road Initiative, leveraging cutting-edge medical technologies from both China and South Africa to establish a thriving industrial base that fosters mutual benefit and complementary growth between China and Africa. Positioned as a highly automated, information-driven, and intelligent hub, the park is designed as an integrated "complex" encompassing R&D, manufacturing, and sales of medical devices—ranging across diverse sectors such as orthopedics, polymers, and protective equipment.
At the symposium, Chen Xingyao, Director of the Medical Device Regulatory Division at the Taizhou Municipal Administration for Market Regulation, provided an in-depth interpretation of the medical device-related policies outlined in the "Thirty Opinions of the Taizhou Municipal Administration for Market Regulation on Further Optimizing the Business Environment and Strengthening Market Entities." Released on February 9, 2022, these "Thirty Opinions" aim to deepen reforms in pharmaceutical, medical device, and cosmetic production and operation approvals, address key challenges hindering the growth of the pharmaceutical industry, expand market opportunities for the sector, and enhance guidance on corporate competition compliance. The initiative seeks to further advance reform, improve service delivery, accelerate processes, boost efficiency, and reduce burdens while lowering costs.
At the meeting, representatives from pharmaceutical companies in Wenling City shared their insights and discussed the operational challenges and bottlenecks that emerged during the pandemic.
After carefully listening to the remarks from representatives of various enterprises, Director Ye stated that the Municipal Bureau will promptly sort through, study, and follow up on the issues raised by the attendees, ensuring that the bottlenecks, challenges, and pain points encountered by pharmaceutical companies in their operations are genuinely addressed. Meanwhile, to further enhance the business environment for pharmaceutical enterprises, the Taizhou Municipal Bureau has also introduced the "Opinions on Boosting the High-Quality Development of the Pharmaceutical and Medical Device Industry," outlining specific measures to accelerate and improve efficiency in review and approval processes, elevate quality standards on implementation platforms, and support companies in upgrading their transformation and growth strategies.
Finally, Director Ye highly praised the contributions made by pharmaceutical companies in the fight against the epidemic, and emphasized:
■ First, all pharmaceutical companies should boost their confidence and remain committed to innovative growth. To achieve this: 1. They must have a comprehensive understanding of the nation’s regulatory policies regarding drugs and medical devices. 2. They should fully capitalize on the benefits outlined in the "30 Opinions of the Taizhou Market Supervision Administration on Further Optimizing the Business Environment and Strengthening Market Entities," which are specifically designed to support and address challenges faced by pharmaceutical firms, ultimately driving high-quality development in our city’s pharmaceutical industry.
■ Second, we must further strengthen accountability and firmly pursue a path of high-quality development. First, companies need to fully assume their primary responsibility for product quality and safety—whether it’s in drug research and development, manufacturing, or distribution and usage—requiring everyone to place even greater emphasis on compliant operations. Second, retail pharmacies must take full ownership of epidemic prevention and control efforts. Given the ongoing severity of the pandemic situation, all major retail pharmacies should rigorously implement all relevant monitoring and prevention measures, effectively fulfilling their critical role as "sentinel points" in the fight against COVID-19.
■ Third, we must fully implement the "Thirty Opinions of the Taizhou Municipal Administration for Market Regulation on Further Optimizing the Business Environment and Strengthening Market Entities." First, we need to ensure smooth communication of policies from the "first mile"—by conducting one-on-one outreach and dissemination efforts. Second, we must effectively bridge the gap in policy implementation down to the "last mile," ensuring that all 30 opinions are genuinely put into practice. This will help create a superior business environment, thereby fostering the growth and development of market entities, especially pharmaceutical companies.
Related Recommendations